peptide research is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-11. Numbers and descriptions here follow the published literature rather than marketing material.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
== Regenerative medicine applications == The MRL/MpJ mouse has attracted considerable attention in the field of regenerative medicine owing to its remarkable capacity for tissue repair in the absence of fibrosis. Insights derived from this model have been investigated for their potential translational relevance to human therapies. One major area of interest is scarless wound healing. The ability of MRL/MpJ mice to regenerate injured tissues without forming scar tissue provides a valuable model for elucidating mechanisms that may help reduce fibrosis in human cutaneous injuries and post-surgical healing. Cardiac regeneration represents another promising avenue. Experimental studies have demonstrated that MRL/MpJ mice are capable of partial myocardial regeneration following injury, suggesting potential strategies for promoting cardiac repair after myocardial infarction. Furthermore, this strain has been employed to investigate mechanisms underlying skeletal muscle repair. Its relative resistance to muscular degeneration has provided insights into potential therapeutic approaches for neuromuscular disorders, including muscular dystrophy. In addition, studies of the MRL/MpJ model have contributed to understanding the role of metabolic regulation in tissue repair. Notably, resistance to diet-induced hyperglycemia in this strain may offer insights into improving wound healing in diabetic conditions.
=== Methemoglobinemia === Methylene blue is used to treat methemoglobinemia by chemically reducing the ferric iron in hemoglobin to ferrous iron. Methemoglobinemia can arise from ingestion of certain pharmaceuticals, toxins, or broad beans in those susceptible. Specifically, it is used to treat methemoglobin levels that are greater than 30% or in which there are symptoms despite oxygen therapy. Normally, through the NADH- or NADPH-dependent methemoglobin reductase enzymes, methemoglobin is reduced back to hemoglobin. When large amounts of methemoglobin occur secondary to toxins, methemoglobin reductases are overwhelmed. Methylene blue, when injected intravenously as an antidote, is itself first reduced to leucomethylene blue, which then reduces the heme group from methemoglobin to hemoglobin. Methylene blue can reduce the half-life of methemoglobin from hours to minutes. At high doses, however, methylene blue actually induces methemoglobinemia, reversing this pathway. Methylene blue is indicated for treating sodium nitrite overdoses, in particular when sodium nitrite is used as part of a suicide attempt.
=== Concatemerization === The concatemerization process generates libraries of concatamers for the ELPs. Concatamers are oligomeric products of ligating a single gene with itself. This will result in repeat segments of a gene, all of which can be transcribed and translated immediately to produce the ELP of interest. A major problem with this synthetic route is that the number of gene repeat segments ligated together to form the concatamer cannot be controlled, leading to ELPs of different sizes, from which the ELP of a desired size must be isolated.
Liquids are useful as lubricants due to their ability to form a thin, freely flowing layer between solid materials. Lubricants such as oil are chosen for viscosity and flow characteristics that are suitable throughout the operating temperature range of the component. Oils are often used in engines, gear boxes, metalworking, and hydraulic systems for their good lubrication properties.
Sources: en.wikipedia.org
Dehydroalanine is an organic compound with the formula CH2=CH(NH2)CO2H. It does not exist in its free form, but it occurs naturally as a residue found in peptides of microbial origin. Unlike most amino acid residues, it has an unsaturated backbone.
As DMR methylation rates decrease (become more hypomethylated), BPD symptom severity measured by the Borderline Symptom List (BSL-23) increases. Additionally, heightened trait impulsivity, measured by the Barratt Impulsivity Scale, and particularly its motor impulsivity subscale, shows inverse relationships with DMR methylation levels. The epigenetic imbalance may also impact social attachment and interpersonal functioning through effects on mu-opioid receptor (MOR). Childhood neglect produces chronic basal understimulation of MORs, which mediate reward and social motivation. Paradoxically, prolonged MOR understimulation may trigger compensatory MOR upregulation in regions such as the amygdala and orbitofrontal cortex. This MOR hypersensitization, with its heightened responsivity to negative affective stimuli, may in turn provoke strong counter-activating KOR responses, resulting in the increased OPRK1 expression observed epigenetically. This KOR-MOR imbalance, where relative KOR overactivity combines with contextually inappropriate MOR hyperexcitability, likely affects BPD's dysregulation of interpersonal relationships and affective instability.
== Medical uses == ACAM2000 is indicated for active immunization against smallpox disease for individuals determined to be at high risk for smallpox infection. It is also indicated for the active prevention of mpox disease in individuals determined to be at high risk for mpox infection.
Sources: en.wikipedia.org
=== Dipeptides === The simplest peptide building blocks are dipeptides. Nanotubes formed from dipeptides are the widest among peptide nanotubes. An example of a dipeptide that has been studied is a peptide from the diphenylalanine motif of the Alzheimer's β-amyloid peptide. Dipeptides have also been shown to self-assemble into hydrogels, another form of nanostructures, when connected to the protecting group Fluorenylmethyloxycarbonyl chloride. Experiments focusing on the dipeptide Fmoc-Diphenylalanine have been conducted that have explored the mechanism in which Fmoc-diphenylalanine self-assembles into hydrogels via π-π interlocked β-sheets. Phenylalanine has an aromatic ring, a crucial part of the molecule due to its high electron-density, which favors self-assembly where the rings stack and enable the assembly to occur.
In most of Central and Eastern Europe, poppy seed is commonly used for traditional pastries and cakes, and it is legal to grow poppies throughout the region, although Germany requires a license. Since January 1999 in the Czech Republic, according to the 167/1998 Sb. Addictive Substances Act, poppies growing in fields larger than 100 square metres (120 sq yd) is obliged for reporting to the local Custom Office. Extraction of opium from the plants is prohibited by law (§ 15 letter d/ of the act). It is also prohibited to grow varieties with more than 0.8% of morphine in dry matter of their capsules, excluding research and experimental purposes (§24/1b/ of the act). The name Czech blue poppy refers to blue poppy seeds used for food. The United Kingdom does not require a license for opium poppy cultivation, but does for extracting opium for medicinal products. When the European Union attempted to ban the cultivation of Papaver somniferum by private individuals on a small scale (such as personal gardens), citizens in EU countries where poppy seed is eaten heavily, such as countries in the Central-Eastern region, strongly resisted the plan, causing the EU to change course.
The climate of Brazil comprises a wide range of weather conditions across a large area and varied topography, but most of the country is tropical. According to the Köppen system, Brazil hosts six major climatic subtypes: desert, equatorial, tropical, semiarid, oceanic and subtropical. The different climatic conditions produce environments ranging from equatorial rainforests in the north and semiarid deserts in the northeast, to temperate coniferous forests in the south and tropical savannas in central Brazil. In Brazil, forest cover is around 59% of the total land area, equivalent to 496,619,600 hectares (ha) of forest in 2020, down from 588,898,000 hectares (ha) in 1990. In 2020, naturally regenerating forest covered 485,396,000 hectares (ha) and planted forest covered 11,223,600 hectares (ha). Of the naturally regenerating forest, 44% was reported to be primary forest (consisting of native tree species with no clearly visible indications of human activity) and around 30% of the forest area was found within protected areas. For 2015, 56% of the forest area was reported to be under public ownership and 44% private ownership. Many regions have starkly different microclimates. An equatorial climate characterizes much of northern Brazil. There is no real dry season, but there are some variations in the period of the year when most rain falls. Temperatures average 25 °C (77 °F), with more significant temperature variation between night and day than between seasons. Over central Brazil, rainfall is more seasonal, characteristic of a savanna climate.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.